rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2020-673-677rsp-2966Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL RESEARCHЭкспрессия интерферон-стимулированных генов (интерфероновый «автограф») у пациентов с ревматоидным артритом: предварительные результатыThe expression of interferon-stimulated genes (interferon “signature”) in patients with rheumatoid arthritis (Preliminary results)АвдееваА. С.AvdeevaA. S.

Авдеева Анастасия Сергеевна

115522, Москва, Каширское шоссе, 34А

Anastasiya S. Avdeeva

115522, Moscow, Kashirskoye Highway, 34A

9056249400@mail.ruhttps://orcid.org/0000-0001-7312-2349ЧетинаЕ. В.TchetinaE. V.

115522, Москва, Каширское шоссе, 34А

Elena V. Tchetina

115522, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0002-3246-1157ЧеркасоваМ. В.CherkasovaM. V.

115522, Москва, Каширское шоссе, 34А

Mariya V. Cherkasova

115522, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0001-5946-5695МарковаГ. А.MarkovaG. A.

115522, Москва, Каширское шоссе, 34А

Galina A. Markova

115522, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0001-7180-1778АртюховА. С.ArtyuhovA. S.

117997, Москва, ул. Островитянова, 1

Alexander S. Artyuhov

117997, Moscow, Ostrovitianova str., 1

https://orcid.org/0000-0002-5640-7139ДашинимаевЭ. Б.DashinimaevE. B.

117997, Москва, ул. Островитянова, 1; 119334, Москва, ул. Вавилова, д. 26

Erdem B. Dashinimaev

117997, Moscow, Ostrovitianova str., 1; 119334, Moscow, Vavilova str., 26

https://orcid.org/0000-0002-1598-8360НасоновЕ. Л.NasonovE. L.

115522, Москва, Каширское шоссе, 34А; 119991, Москва, ул. Трубецкая, 8, стр. 2

Evgeny L. Nasonov

115522, Moscow, Kashirskoye Highway, 34A; 119991, Moscow, Trubetskaya str., 8, building 2

ФГБНУ Научно-исследовательский институт ревматологии им В.А. НасоновойРоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationНИИ трансляционной медицины ФГАОУ ВО Российский национальный исследовательский медицинский университет им. Н.И. Пирогова Минздрава РоссииРоссияResearch Institute of Translational Medicine, N.I. Pirogov Russian National Research Medical UniversityRussian FederationНИИ трансляционной медицины ФГАОУ ВО Российский национальный исследовательский медицинский университет им. Н.И. Пирогова Минздрава России; ФГБУН Институт биологии развития им. Н.К. Кольцова, РАНРоссияResearch Institute of Translational Medicine, N.I. Pirogov Russian National Research Medical University; Koltzov Institute of Developmental Biology of Russian Academy of SciencesRussian FederationФГБНУ Научно-исследовательский институт ревматологии им В.А. Насоновой; ФГАОУ ВО Первый Московский государственный университет им. И.М. Сеченова Минздрава России (Сеченовский Университет)РоссияV.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University (Sechenovskiy University)Russian Federation202013012021586673677Copyright © Авдеева А.С., Четина Е.В., Черкасова М.В., Маркова Г.А., Артюхов А.С., Дашинимаев Э.Б., Насонов Е.Л., 20212021Авдеева А.С., Четина Е.В., Черкасова М.В., Маркова Г.А., Артюхов А.С., Дашинимаев Э.Б., Насонов Е.Л.Avdeeva A.S., Tchetina E.V., Cherkasova M.V., Markova G.A., Artyuhov A.S., Dashinimaev E.B., Nasonov E.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2966Цель исследования

Цель исследования. Оценить экспрессию интерферон-стимулированных генов у пациентов с ревматоидным артритом (РА).

Материал и методы

Материал и методы. Обследовано 20 больных с РА. Все пациенты получали терапию метотрексатом в стабильной дозе (Ме 15 [10-17,5] мг) не менее 4 недель. Для оценки интерферонового «автографа» (TypeIIFNGeneSignature - IFNGS) были отобраны пять генов (IFI44L, MX1, IFIT1, RSAD2, EPSTI1). Экспрессию IFI44L и IFIT1 определить не удалось, и в дальнейшем анализе учитывались три гена - MX1, EPSTI1, RSAD2.

Результаты

Результаты. Исходный уровень экспрессии MX1 - 11,48 [5,45-19,38], EPSTI1 - 12,83 [5,62-19,64], RSAD2 -5,16 [2,73-10,4] и IFNGS - 10,3 [5,18-17,12] у пациентов с РА был достоверно выше по сравнению со здоровыми донорами - 1,26 [0,73-1,6], 1,06 [0,81-1,48], 0,93 [0,72-1,19] и 1,09 [0,92-1,42] соответственно (р<0,05). IFNGS был обнаружен у 15 (75%) пациентов, отсутствовал - у 5 (15%) больных. Выявлена позитивная корреляционная взаимосвязь IFNGS и уровня экспрессии EPSTI1 с длительностью терапии метотрексатом (r=0,46, р=0,03). Среди пациентов, получавших метотрексат более одного года, отмечалась тенденция к более высокому уровню экспрессии EPSTI1 (10,74 [12,6-32,8]) и ИФН score (16,2 [8,9-38,3]) по сравнению с больными, принимавшими метотрексат менее года (9,67 [5,4-14,2] и 7,9 [4,5-13,4]; (р=0,06).

Заключение

Заключение. Предварительные результаты по оценке IFNGS свидетельствуют о повышенной экспрессии интерферон-стимулированных генов у пациентов с РА, что может иметь значение для прогнозирования течения заболевания и персонификации терапии.

Objective

Objective. To assess the expression of interferon-stimulated genes in patients with rheumatoid arthritis (RA).

Material and methods

Material and methods. Twenty patients with RA were examined. All patients received methotrexate therapy at a stable dose (Me 15 [10-17.5] mg) for at least 4 weeks. To assess the Type I IFN gene signature (IFNGS) we selected five genes (IFI44L, MX1, IFIT1, RSAD2, EPSTI1). The expression of IFI44L and IFIT1 could not be determined, and further analysis took into account three genes - MX1, EPSTI1, RSAD2.

Results

Results. Baseline level of MX1 expression - 11.48 [5.45-19.38], EPSTI1 - 12.83 [5.62-19.64], RSAD2 - 5.16 [2.7310.4] and IFN score - 10.3 [5.18-17.12] in patients with rheumatoid arthritis was significantly higher compared with healthy donors - 1.26 [0.73-1.6], 1.06 [0.81-1.48], 0.93 [0.72-1.19], and 1.09 [0.92-1.42] respectively, p<0.05. IFN signature was found in 15 (75%) patients, was absent - in 5 (15%) patients. A positive correlation was found between the IFNGS and the level of EPSTI1 expression with the duration of methotrexate therapy (r=0.46, p=0.03). Among patients who received methotrexate therapy for more than one year, there was a tendency to a higher level of EPSTI1 expression (10.74 [12.6-32.8]) and IFNGS (16.2 [8.9-38.3]) compared with patients taking methotrexate for less than a year (9.67 [5.4-14.2] and 7.9 [4.5-13.4]), (p=0.06).

Conclusion

Conclusion. Preliminary results on the assessment of IFNGS indicate an increased expression of IFN-stimulated genes in patients with RA, which may be important for predicting the course of the disease and personalizing therapy.

ревматоидный артритинтерфероновый «автограф»интерферон-стимулированные геныrheumatoid arthritisinterferon signatureinterferon-stimulated genesИсследование проводилось в рамках выполнения научной темы № 397 «Эволюция ранних артритов и разработка инновационных технологий фармакотерапии ревматических заболеваний у детей и взрослых» — АААА-А19-119021190149-0ReferencesSmolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001. DOI: 10.1038/nrdp.2018.1Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001. DOI: 10.1038/nrdp.2018.1McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017;389(10086):2328-2337. DOI: 10.1016/S0140-6736(17)31472-1McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017;389(10086):2328-2337. DOI: 10.1016/S0140-6736(17)31472-1Lewis MJ, Barnes MR, Blighe K, Goldmann K, Rana S, Hackney JA, et al. Molecular portraits of early rheumatoid arthritis identify clinical and treatment response phenotypes. Cell Rep. 2019;28(9):2455-2470.e5. DOI: 10.1016/j.celrep.2019.07.091Lewis MJ, Barnes MR, Blighe K, Goldmann K, Rana S, Hackney JA, et al. Molecular portraits of early rheumatoid arthritis identify clinical and treatment response phenotypes. Cell Rep. 2019;28(9):2455-2470.e5. DOI: 10.1016/j.celrep.2019.07.091McGonagle D, Watad A, Savic S. Mechanistic immunological based classification of rheumatoid arthritis. Autoimmun Rev. 2018;17(11):1115-1123. DOI: 10.1016/j.autrev.2018.06.001McGonagle D, Watad A, Savic S. Mechanistic immunological based classification of rheumatoid arthritis. Autoimmun Rev. 2018;17(11):1115-1123. DOI: 10.1016/j.autrev.2018.06.001Насонов Е.Л., Авдеева А.С. Иммуновоспалительные ревматические заболевания, связанные с интерфероном типа I: новые данные. Научно-практическая ревматология. 2019;57(4):452-461. DOI: 10.14412/1995-4484-2019-452-461Immunoinflammatory rheumatic diseases associated with type I interferon: New evidence]. Nauchno-prakticheskaya revmatologi-ya=Rheumatology Science and Practice. 2019;57(4):452-461. (In Russian). DOI: 10.14412/1995-4484-2019-452-461Psarras A, Emery P, Vital EM. Type I interferon-mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy. Rheumatology (Oxford). 2017;56(10):1662-1675. DOI: 10.1093/rheumatology/kew431Psarras A, Emery P, Vital EM. Type I interferon-mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy. Rheumatology (Oxford). 2017;56(10):1662-1675. DOI: 10.1093/rheumatology/kew431Muskardin TLW, Niewold TB. Type I interferon in rheumatic diseases. Nat Rev Rheumatol. 2018;14(4):214-228. DOI: 10.1038/nrrheum.2018.31Muskardin TLW, Niewold TB. Type I interferon in rheumatic diseases. Nat Rev Rheumatol. 2018;14(4):214-228. DOI: 10.1038/nrrheum.2018.31Banchereau R, Cepika AM, Banchereau J, Pascual V. Understanding human autoimmunity and autoinflammation through transcriptomics. Annu Rev Immunol. 2017;35:337-370. DOI: 10.1146/annurev-immunol-051116-052225Banchereau R, Cepika AM, Banchereau J, Pascual V. Understanding human autoimmunity and autoinflammation through transcriptomics. Annu Rev Immunol. 2017;35:337-370. DOI: 10.1146/annurev-immunol-051116-052225Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol. 2014;32:513-545. DOI: 10.1146/annurev-immunol-032713-120231Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol. 2014;32:513-545. DOI: 10.1146/annurev-immunol-032713-120231Lubbers J, Brink M, van de Stadt LA, Vosslamber S, Wasseling JG, van Schaardenburg D, et al. The type I IFN signature as a biomarker of preclinical rheumatoid arthritis. Ann Rheum Dis. 2013;72(5):776-80. doi: 10.1136/annrheumdis-2012-202753Lubbers J, Brink M, van de Stadt LA, Vosslamber S, Wasseling JG, van Schaardenburg D, et al. The type I IFN signature as a biomarker of preclinical rheumatoid arthritis. Ann Rheum Dis. 2013;72(5):776-80. doi: 10.1136/annrheumdis-2012-202753van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Voskuyl AE, Rustenburg F, Baggen JM, et al. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis. 2007;66(8):1008-14. DOI: 10.1136/ard.2006.063412van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Voskuyl AE, Rustenburg F, Baggen JM, et al. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis. 2007;66(8):1008-14. DOI: 10.1136/ard.2006.063412De Jong TD, Blits M, de Ridder S, Vosslamber S, Wolbink G, Nurmohamed MT, et al. Type I interferon response gene expression in established rheumatoid arthritis is not associated with clinical parameters. Arthritis Res Ther. 2016;18(1):290. DOI: 10.1186/s13075-016-1191-yDe Jong TD, Blits M, de Ridder S, Vosslamber S, Wolbink G, Nurmohamed MT, et al. Type I interferon response gene expression in established rheumatoid arthritis is not associated with clinical parameters. Arthritis Res Ther. 2016;18(1):290. DOI: 10.1186/s13075-016-1191-yDe Jong TD, Snoek T, Mantel E, van der Laken CJ, van Vollen-hoven RF, Lems WF. Dynamics of the type I interferon response during immunosuppressive therapy in rheumatoid arthritis. Front Immunol. 2019;10:902. DOI: 10.3389/fimmu.2019.00902De Jong TD, Snoek T, Mantel E, van der Laken CJ, van Vollen-hoven RF, Lems WF. Dynamics of the type I interferon response during immunosuppressive therapy in rheumatoid arthritis. Front Immunol. 2019;10:902. DOI: 10.3389/fimmu.2019.00902Rodriguez-Carrio J, Alperi-LOpez M, Lopez P, Ballina-Garcia FJ, Suarez A. Heterogeneity of the type I interferon signature in rheumatoid arthritis: A potential limitation for its use as a clinical biomarker. Front Immunol. 2018;8:2007. DOI: 10.3389/fimmu.2017.02007Rodriguez-Carrio J, Alperi-LOpez M, Lopez P, Ballina-Garcia FJ, Suarez A. Heterogeneity of the type I interferon signature in rheumatoid arthritis: A potential limitation for its use as a clinical biomarker. Front Immunol. 2018;8:2007. DOI: 10.3389/fimmu.2017.02007Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham III CO, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-2581. DOI: 10.1002/art.27584Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham III CO, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-2581. DOI: 10.1002/art.27584Rodriguez-Carrio J, LOpez P, Alperi-LOpez M, Caminal-Montero L, Ballina-Garcia FJ, Sudrez A. IRF4 and IRGs delineate clinically relevant gene expression signatures in systemic lupus erythematosus and rheumatoid arthritis. Front Immunol. 2019;9:3085. DOI: 10.3389/fimmu.2018.03085Rodriguez-Carrio J, LOpez P, Alperi-LOpez M, Caminal-Montero L, Ballina-Garcia FJ, Sudrez A. IRF4 and IRGs delineate clinically relevant gene expression signatures in systemic lupus erythematosus and rheumatoid arthritis. Front Immunol. 2019;9:3085. DOI: 10.3389/fimmu.2018.03085Raterman HG, Vosslamber S, de Ridder S, Nurmohamed MT, Lems WF, Boers M. The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Res Ther. 2012;14(2):R95. DOI: 10.1186/ar3819Raterman HG, Vosslamber S, de Ridder S, Nurmohamed MT, Lems WF, Boers M. The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Res Ther. 2012;14(2):R95. DOI: 10.1186/ar3819Thurlings RM, Boumans M, Tekstra J, van Roon JA, Vos K, van Westing DM, et al. Relationship between the type I interferon sig nature and the response to rituximab in rheumatoid arthritis patients. Arthritis Rheum. 2010;62 (12):3607-14. doi: 10.1002/art.27702.Thurlings RM, Boumans M, Tekstra J, van Roon JA, Vos K, van Westing DM, et al. Relationship between the type I interferon sig nature and the response to rituximab in rheumatoid arthritis patients. Arthritis Rheum. 2010;62 (12):3607-14. doi: 10.1002/art.27702.Cooles FAH, Anderson AE, Lendrem DW, Norris J, Pratt AG, Hilkens CMU, et al. The interferon gene signature is increased in patients with early treatment-naive rheumatoid arthritis and predicts a poorer response to initial therapy. J Allergy Clin Immunol. 2018;141(1):445-448.e4. DOI: 10.1016/j.jaci.2017.08.026Cooles FAH, Anderson AE, Lendrem DW, Norris J, Pratt AG, Hilkens CMU, et al. The interferon gene signature is increased in patients with early treatment-naive rheumatoid arthritis and predicts a poorer response to initial therapy. J Allergy Clin Immunol. 2018;141(1):445-448.e4. DOI: 10.1016/j.jaci.2017.08.026de Jong TD, Vosslamber S, Blits M, Wolbink G, Nurmohamed MT, van der Laken CJ. Effect of prednisone on type I interferon signature in rheumatoid arthritis: Consequences for response prediction to rituximab. Arthritis Res Ther. 2015;17(1):78. DOI: 10.1186/s13075-015-0564-yde Jong TD, Vosslamber S, Blits M, Wolbink G, Nurmohamed MT, van der Laken CJ. Effect of prednisone on type I interferon signature in rheumatoid arthritis: Consequences for response prediction to rituximab. Arthritis Res Ther. 2015;17(1):78. DOI: 10.1186/s13075-015-0564-yvan Baarsen LG, Wijbrandts CA, Rustenburg F, Cantaert T, van der Pouw Kraan TCTM, Baeten DL, et al. Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment. Arthritis Res Ther. 2010;12(1):R11. doi: 10.1186/ar2912.van Baarsen LG, Wijbrandts CA, Rustenburg F, Cantaert T, van der Pouw Kraan TCTM, Baeten DL, et al. Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment. Arthritis Res Ther. 2010;12(1):R11. doi: 10.1186/ar2912.Garcia-Montoya L, Wigston Z, Burska A, Mankia K, Vital E, Emery P. THU0015 Type I interferon signature predicts progression to inflammatory arthritis in ACPA+ at-risk individuals without clinical synovitis. Ann Rheum Dis. 2020;79:220-221.Garcia-Montoya L, Wigston Z, Burska A, Mankia K, Vital E, Emery P. THU0015 Type I interferon signature predicts progression to inflammatory arthritis in ACPA+ at-risk individuals without clinical synovitis. Ann Rheum Dis. 2020;79:220-221.Yokoyama-Kokuryo W, Yamazaki H, Takeuchi T, Amano K, Kikuchi J, Kondo T, et al. Identification of molecules associated with response to abatacept in patients with rheumatoid arthritis. Arthritis Res Ther. 2020;22(1):46. doi: 10.1186/s13075-020-2137-yYokoyama-Kokuryo W, Yamazaki H, Takeuchi T, Amano K, Kikuchi J, Kondo T, et al. Identification of molecules associated with response to abatacept in patients with rheumatoid arthritis. Arthritis Res Ther. 2020;22(1):46. doi: 10.1186/s13075-020-2137-yWright HL, Thomas HB, Moots RJ, Edwards SW. Interferon gene expression signature in rheumatoid arthritis neutrophils correlates with a good response to TNFi therapy. Rheumatology (Oxford). 2015;54(1):188-193. DOI: 10.1093/rheumatology/keu299Wright HL, Thomas HB, Moots RJ, Edwards SW. Interferon gene expression signature in rheumatoid arthritis neutrophils correlates with a good response to TNFi therapy. Rheumatology (Oxford). 2015;54(1):188-193. DOI: 10.1093/rheumatology/keu299Насонов ЕЛ, Лила АМ. Ингибиторы янус-киназ при иммуно-воспалительных ревматических заболеваниях: новые возможности и перспективы. Научно-практическая ревматология. 2019;57(1):8-16. DOI: 10.14412/19954484-2019-8-16Nasonov EL, Lila AM. Ingibitory yanus-kinaz pri immunovospalitel’nykh revmaticheskikh zabolevaniyakh: novye vozmozhnosti i perspektivy [Janus kinase inhibitors in immuno-in-flammatory rheumatic diseases: New opportunities and prospects]. Nauchno-prakticheskaya revmatologiya=Rheumatology Science and Practice. 2019;57(1):8-16. (In Russian). DOI: 10.14412/19954484-2019-8-16Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382(3):211-221. DOI: 10.1056/NEJMoa1912196Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382(3):211-221. DOI: 10.1056/NEJMoa1912196Smith MA, Chiang CC, Zerrouki K, Rahman S, White WI, Streicher K, et al. Using the circulating proteome to assess type I interferon activity in systemic lupus erythematosus. Sci Rep. 2020;10(1):4462. doi: 10.1038/s41598-020-60563-9.Smith MA, Chiang CC, Zerrouki K, Rahman S, White WI, Streicher K, et al. Using the circulating proteome to assess type I interferon activity in systemic lupus erythematosus. Sci Rep. 2020;10(1):4462. doi: 10.1038/s41598-020-60563-9.

The authors declare that there are no conflicts of interest present.